BioRestorative Therapies (OTCMKTS:BRTX – Get Free Report) is one of 459 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its competitors? We will compare BioRestorative Therapies to similar businesses based on the strength of its profitability, analyst recommendations, valuation, earnings, risk, institutional ownership and dividends.
Institutional and Insider Ownership
69.4% of BioRestorative Therapies shares are held by institutional investors. Comparatively, 31.4% of shares of all “Biotechnology” companies are held by institutional investors. 21.6% of BioRestorative Therapies shares are held by company insiders. Comparatively, 20.7% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares BioRestorative Therapies and its competitors top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
BioRestorative Therapies | $145,800.00 | -$18.50 million | -0.39 |
BioRestorative Therapies Competitors | $161.52 million | -$11.04 million | 65.02 |
Volatility and Risk
BioRestorative Therapies has a beta of 61.51, indicating that its share price is 6,051% more volatile than the S&P 500. Comparatively, BioRestorative Therapies’ competitors have a beta of 1.19, indicating that their average share price is 19% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent ratings and target prices for BioRestorative Therapies and its competitors, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
BioRestorative Therapies | 0 | 0 | 1 | 0 | 3.00 |
BioRestorative Therapies Competitors | 1019 | 2696 | 6148 | 76 | 2.53 |
BioRestorative Therapies currently has a consensus price target of $15.00, indicating a potential upside of 994.89%. As a group, “Biotechnology” companies have a potential upside of 93.88%. Given BioRestorative Therapies’ stronger consensus rating and higher probable upside, research analysts clearly believe BioRestorative Therapies is more favorable than its competitors.
Profitability
This table compares BioRestorative Therapies and its competitors’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
BioRestorative Therapies | -13,728.83% | -120.47% | -114.48% |
BioRestorative Therapies Competitors | -8,222.02% | -127.38% | -27.03% |
Summary
BioRestorative Therapies beats its competitors on 7 of the 13 factors compared.
About BioRestorative Therapies
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.
Receive News & Ratings for BioRestorative Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioRestorative Therapies and related companies with MarketBeat.com's FREE daily email newsletter.